Research Development Services office will continue to actively support the Mason community during the time of reduced campus operations. All staff will be working remotely but continue to provide support to faculty, students and staff in managing the Limited Submission Opportunities and internal application reviews as needed; creating training materials for proposal development; providing proposal management and support for large, complex, multidisciplinary proposals; and offering guidance on seeking funding opportunities through the Sponsored Programs Innovation Network (SPIN). All staff will be working remotely. Please feel free to contact Rebekah Hersch, Assistant Vice President, Research Development (email@example.com) if you have questions. For information about the Limited Submission Opportunities, please contact Sheila Davis (firstname.lastname@example.org).
COVID-19 Datasets and Analytic Resources
- Academic Data Science Alliance is curating and updating a list of open datasets and analytic resources on their website. You can find more information on available datasets and resources here: www.academicdatascience.org/covid
- NLM released the COVID-19 Open Research Dataset (CORD-19) of scholarly literature related to COVID-19, SARS-CoV-2, and the Coronavirus group. To make full of this dataset, the White House Office of Science and Technology Policy (OSTP) has issued a call for tech and AI experts to develop new text and data mining techniques that can be used to help the science community answer high-priority scientific questions related to COVID-19.
- The Pittsburgh Supercomputing Center (PSC) is currently hosting the COVID-19 database for the National Genomics Data Center of the Chinese People’s Republic. By providing ready access to this important dataset, they hope to enable researchers to better understand the COVID-19 virus. https://www.psc.edu/bridges-for-covid-19-research
- The scientific platform Galaxy at the Pennsylvania State University has developed an open source set of computer tools for helping scientists studying the COVID-19 virus obtain transparent and reproducible results. For more information see https://covid19.galaxyproject.org/
- NVIDIA is providing a software called Parabricks free for 90 days to organizations doing research on COVID19. The Argo cluster meets the minimum requirements. Please contact Jayshree Sarma (email@example.com) if you are interested in using the software. https://blogs.nvidia.com/blog/2020/03/19/coronavirus-research-parabricks/?ncid=em-news-57155#cid=ix01_em-news_en-us . Parabricks software (https://www.developer.nvidia.com/nvidia-parabricks) is used for genome sequencing and uses GPU (Graphical Processing Unit) for speeding up the analysis.
- Georgetown COVID-19 Open Research Dataset: https://pages.semanticscholar.org/coronavirus-research
- The COVID-19 High Performance Computing Consortium: Researchers interested in applying for COVID-19 research allocation on the XSEDE supercomputers can apply here: https://campuschampions.web.illinois.edu
- Facebook Enabling COVID-19 Research with New Data Sets. To support ongoing COVID-19 research and to help inform public health decisions, CMU and UMD made the aggregated data from these surveys publicly available. Learn more here: https://research.fb.com/blog/2020/05/expanding-support-for-covid-19-research-through-the-symptom-surveys/
- The National Science Foundation has awarded the University of Virginia a $1.2 million expansion of a grant to develop a secure, high-performance computing system for research, with the new funds supporting nationwide use of the system for COVID-19 research. Learn more here: https://www.hpcwire.com/off-the-wire/uva-leads-nationwide-project-to-protect-health-data-for-covid-19-research/ (Additional funding is available to all COVID-19 research at Mason)
COVID-19 Funding Opportunities
The following table lists funding opportunities relating to the COVID-19 virus. We will continue to update this list as new opportunities become available. If you would like to add opportunities to this list please feel free to contact Heather Arold at firstname.lastname@example.org.
|Program Title||Sponsor||Deadline||Funding Amount||Brief Synopsis|
|Fast Grants||Emergent Ventures||None Posted||$500,000||Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants will range from $10,000 to $500,000.|
|Health, Science, and Technology RFP: COVID-19, Smoking & Nicotine Research||Foundation for a Smoke-Free World||15-Dec-20||Not Available||The Foundation for a Smoke-free World is seeking to conduct research at the nexus of COVID-19, smoking, and nicotine that will require significant collaboration and research efforts with outside experts and organizations. We seek to advance knowledge of value to science and policy in these areas. The selected organization(s) will implement a range of projects relevant to the global pandemic, including well-designed and comprehensive pre-clinical, clinical, and epidemiological studies, to better understand the associations between smoking and / or nicotine use, and COVID-19 infection and outcomes.|
|RFA-OD-029 -- The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trail Optional)||Office of Research on Women's Health/NIH||25-Oct-2020 (LOI/Pre-App)||$1,400,000||The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through thd Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH.|
|Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||National Institute of Health||5-Oct-20||Not Available||The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).|
|Medical Education Grants: The Burden and Origins of Co-Infections in COVID-19 Pneumonia||Pfizer Pharmaceuticals||15-Oct-20||$250,000||Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals (RFP) to support virtual educational programs that raise awareness on epidemiology, treatment patterns and outcomes of pulmonary bacterial and fungal co-infections and superinfections in COVID-19 hospitalized patients. Individual projects requesting up to $250,000 will be considered.|
|Research Innovation Collaborations Program||23andme||12-Dec-20||Not Available||23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.|
|Call for Tender: Rebuilding Better: Opportunities and Risks in the Context of COVID-19||British Embassy to France||3-Oct-20||$38,400||The British Embassy to France is seeking a partner organisation(s) to deliver an innovative and exciting research project, under our supervision, including papers and events for the period October 2020 to February 2021.|
|COVID-19 Symptom Data Challenge||Catalyst @ Health 2.0||29-Sep-20||$50,000||The COVID-19 Symptom Data Challenge is a competition to develop a novel analytic approach that uses the CMU/UMD COVID-19 Symptom Survey data to enable earlier detection and improved situational awareness of the outbreak by public health authorities and the general public. Semi-finalists and finalists are eligible for cash prizes, and finalists will join discussions with partners on how to improve and deploy their submissions.|
|COVID-19 Medical Countermeasures Consultant Support||Department of Defense||None Posted||Not Available||1. Scope: The current COVID-19 pandemic demands immediate action in developing life-saving Medical Countermeasures (MCM), which encompass technical efforts from early development through their Food and Drug Administration (FDA) approval. This document provides a summary of the Department of Defense (DOD) and Operation Warp Speed (OWS) major integrated efforts that include but are not limited to leveraging the use of Senior Subject Matter Experts (SMEs) consultants with recognized expertise in MCM development in a variety of disciplines, such as: diagnostics, vaccines, polyclonal antibodies (pAbs), and large and small molecule drug development efforts from early development through FDA approval and Post Licensure related efforts. The Government will draw upon consultant expertise of SMEs to support the Joint Program Executive Office, Chemical, Biological, Radiological & Nuclear Defense (JPEO-CBRND) mission through the development of MCM in the three major MCM domains: Diagnostics, Prevention, and Treatment for COVID-19. SMEs will include senior pharmaceutical technical experts to ensure the JPEO can accomplish the mission to deliver MCMs to DoD personnel and to the nation. Nested within these major integrated MCM development efforts are numerous technical challenges to clinical, non-clinical, and manufacturing processes, up to full scale production to obtain FDA approval. The consultant pharmaceutical SMEs will augment DOD MCM developers and contribute to analysis, assessment, design, and evaluation of alternative approaches to achieve the rapid development of MCMs against COVID-19. They will increase efficiency and effectiveness, reduce the risks, and shorten the schedule of delivering MCMs to protect the U.S. military, coalition forces, and the nation from the current COVID-19 pandemic. 2. The Government has determined that the need to accelerate COVID-19 development is of such an unusual and compelling urgency (FAR.6.302-2) that the Government has pursued a sole source procurement for the consultant services described above. The contract will have a Base Period of six (6) months duration, with the option to extend services in accordance with FAR 52.217-9 for a further six months.|
|Call for Proposals - On Aging 2021||American Society on Aging (ASA)||30-Sep-20||Not Available||ASA’s impact is guided by five intersecting areas: social justice, health and wellbeing, economic security, ageism and culture, and innovation and social impact. Moving into 2021, the sponsor wants to especially consider how the issue of equity intertwines all of these areas.|
|Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract||National Institute of Child Health and Human Development||5-Oct-20||5-Oct-20||The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.|
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action||None Posted||Not Available||The Peace & Recovery (P&R) Program supports field experiments and related research on reducing violence and fragility, promoting peace, and preventing, managing, and recovering from crises. Currently, the sponsor is accepting Research Proposals for COVID-19 Response and Off-Cycle Research Proposals for Research on Homicide Reduction in Latin America and the Caribbean.|
|RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial NOT Allowed)||National Institute of Environmental Health Sciences/NIH/DHHS||1-Oct-20||$275,000||This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.|
|ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research||Association for Computing Machinery||8-Oct-20||$10,000||The Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research will be awarded in 2020 and 2021 to recognize outstanding research achievement towards the understanding of the COVID-19 pandemic through the use of high-performance computing (HPC). The purpose of the award is to recognize the innovative parallel computing contributions towards the solution of the global crisis. Nominations will be selected based on performance and innovation in their computational methods, in addition to their contributions towards understanding the nature, spread and/or treatment of the disease. Financial support of this $10,000 award is provided by Gordon Bell, a pioneer in high-performance and parallel computing.|
|China-IFAD South-South and Triangular Cooperation Facility: Third Call for Proposals||International Fund for Agricultural Development (IFAD)||31-Oct-20||$500,000||The China-IFAD South-South and Triangular Cooperation Facility pursues the overarching objective of mobilizing knowledge, technologies and resources from the Global South to accelerate rural poverty alleviation, enhance rural productivity, and advance rural transformation.|
|Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)||National Institute on Drug Abuse/NIH/DHHS||6-Oct-20||$275,000||This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research collecting and examining data on the risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).|
|RFA-HD-21-023 -- NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)||National Institute of Child Health and Human Development||1-Mar-21||$3,000,000||This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.|
|2020 TIP Office Annual Program Statement to Address the Impacts of COVID-19||Department of State||30-Sep-20||$100,000||The Department of State’s Office to Monitor and Combat Trafficking in Persons (TIP Office) announces an open competition for funding to address the impacts of COVID-19 on efforts to combat human trafficking and support government measures to counter human trafficking. Applicants are encouraged to propose activities that will help organizations and partner governments continue to combat trafficking in persons despite these challenges. Applicants are encouraged to note recommendations in the TIP Report and link proposed activities to the recommendations. Applicants may submit applications for no less than $100,000.|
|RFA-OD-20-016 -- Emergency Awards: RADx-RAD Multimodal COVID-19 Surveillance Methods for High Risk Clustered Populations (R01 Clinical Trial Optional)||National Institutes of Health/DHHS||5-Oct-20||Not Available||This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate.|
|Small Grants Program in Behavioral Economics||Sage (Russell) Foundation||None Posted||$8,500||The Russell Sage Behavioral Economics Roundtable supports a small grants research program to support high quality research in behavioral economics and to encourage young investigators (Ph.D. students and recent graduates) to enter this developing field.|
|Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations||National Institutes of Health/DHHS||15-Dec-20||$250,000||This notice invites competitive and administrative supplements for community interventions to reduce the impact of COVID-19 on health disparity and other vulnerable populations.|
|COVID-19 Vaccines: Accelerating Vaccine Development and Global Manufacturing Capacity to Stop the Pandemic||Coalition for Epidemic Preparedness Innovations (CEPI)||None Posted||Not Available||The objective of this Call for Proposals is to support the rapid development of vaccines against COVID-19 with a goal of achieving licensure/emergency authorisation in 12-18 months or less and to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021.|
|SARS-CoV-2 (COVID-19) Program Activities||Assistant Secretary of Health/DHHS OS-PAW||None Posted||None Posted||The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19…” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.|
|Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing||Department of the Army||28-Feb-21||Not Available||Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing. This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and operational utility of a product to move forward to FDA licensure/approval.|
|6640--COVID-19 Cephieid Equipment COVID-19 Testing Emergency Requirement||Department of Veterans Affairs||None Posted||Not Available||Description of Supplies or Services: The estimated value of the proposed action is $ 323,040.00. Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV2, the virus that causes COVID-19 on the GeneXpert Systems. Cepheid is the only authorized US manufacturer and distributor of this instrumentation for polymerase chain reaction (PCR) molecular technology. These instruments are also compatible and will integrate with systems currently installed in the facilities, streamlining the validation and implementation process.|
|PCORI Funding Announcement: Phased Large Awards in Comparative Effectiveness Research (PLACER)||Patient-Centered Outcomes Research Institute (PCORI)||29-Sep-20||Not Available||This Patient-Centered Outcomes Research Institute (PCORI) funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions. Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions are appropriate for study.|
|FDA Influenza Immunity and Vaccination Postdoctoral Fellowship||Oak Ridge Institutes for Science and Education||30-Sep-20||Not Available||A research opportunity is currently available in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.|
|FDA COVID-19 Diagnostic Test Fellowship||Oak Ridge Institutes for Science and Education||30-Sep-20||Not Available||A research opportunity is currently available in the laboratory of Dr. Paul Carlson in the Office of Vaccine Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.|
|RFA-HG-20-039 -- Laboratory Data Analysis, and Coordinating Center (LDACC) for the Development of Genotype-Tissue Expression Project (U24 Clinical Trial Not Allowed)||National Institutes for Health/DHHS||13-Oct-20||Not Available||The National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development are coordinating efforts for establishing a Developmental Genotype-Tissue Expression (dGTEx) Project, to catalog and analyze transcriptional profiles from a wide variety of tissues obtained from neonates, children, and adolescents in a post-mortem setting. The purpose of this FOA is to solicit applications to develop and implement a Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression (dGTEx) Project. The LDACC will perform 2 major functions: a molecular laboratory, and a data analysis and coordinating center. As a molecular laboratory, the LDACC will work with the Biospecimen Procurement Center (BPC) funded by NICHD to process tissue samples for sequencing and biobanking. Responsibilities as a data analysis and coordinating center include ensuring close coordination with the BPC, monitoring study progress and laboratory performance, performing basic analysis of data for gene expression analyses, and harmonizing and submitting datasets to be deposited in repositories such as the AnVIL (Analysis, Visualization, and Informatics Lab-space).|
|Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Health Need||National Institutes of Health/DHHS||10-Nov-20||Not Available||The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.|
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||None Posted||Not Available||National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 18.104.22.168 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes for Health/DHHS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.|
|RFA-RM-20-020 -- NIH Director's Emergency Transformative Research Awards (R01 Clinical Trial Optional)||National Institutes of Health/NIH/DHHS||30-Sep-20||Not Available||This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES-Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013. The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce.|
|Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health||Ferring Pharmaceuticals||Oct. 31, 2020||25,000 EUR||Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects of SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health are designed to provide funding to gather data related to IVF programmes during the COVID-19 pandemic including but not limited to follow-up data on infected pregnant patients at different gestational stages, including spontaneous pregnancies; data on the outcome of ongoing fertility care; data on gametes/embryos, fresh or frozen, from patients exposed to SARS-CoV-2; and other information related to fertility outcomes.|
|Covid-19 Scientific Research||European Synchrotron Radiation Facility||None Posted||Not Available||The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.|
|Grants Program||COVID-19 Early Treatment Fund (CETF)||None Posted||Not Available||CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHSS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.|
|2020 COVID-19 FlexGrants||West Coast Consortium for Technology & Innovation in Pediatrics||None Posted||$15,000||The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.|
|Medical Robotics for Contagious Diseases Challenge||EPSRC UK-Robotics Autonomous Systems (UK-RAS) Network||9/30/2020||Not Available||The UK-RAS Network is pleased to announce a new Medical Robotics Challenge for Contagious Diseases. The outbreak of novel coronavirus has sparked a global health crisis and the robotics research and innovation communities from an integral part of our response. Now more than ever, it is evident that robotics has a key role to play. Across the world, robots and drones are being repurposed and deployed as part of the COVID-19 response.|
|Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)||Department of Health & Human Services||10/31/2020||Not Available||We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur.|
|ICESCO Prize for Fighting Against Coronavirus||Islamic World Education, Scientific, and Cultural Organization||None Posted||$200,000||In response to the World Health Organization's appeal to the international community to "seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact", the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.|
|COVID-19 Response: A Call for Ideas||COVID-19 Response: A Call for Ideas||None Posted||Not Available||The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.|
|Access to Platform for Partner COVID-19 Projects||Ginkgo Bioworks||None Posted||Not Available||Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.|
|Expedited, Rapid Access Call for COVID-19 Research||Argonne National Laboratory||None Posted||Not Available||Argonne National Laboratory|
|COVID-19 Research Support||Brookhaven National Laboratory||None Posted||Not Available||The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.|
|COVID-19 Vaccine Development Award||MMS Holdings Inc.||None Posted||$1,000,000||The sponsor is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.|
|RFA-DA-20-028 -- Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required)||National Institute on Drug Abuse/NIH/DHHS||10/14/2020||Not Available||NIDA is interested in research that addresses research gaps related to the delivery of integrated treatment services for HIV and opioid use disorder (OUD) among the justice-involved population in the US, with a goal of improving treatment management and implementation. A quarter of all people infected with HIV pass through the justice system each year, making it an important system for HIV prevention and treatment. Community re-entry from incarceration is a time of heightened risk for opioid relapse, mortality, HIV risk behaviors, and discontinuation of HIV treatment. Given these elevated levels of risk, justice-involved people who inject drugs (PWID) should be prioritized for screening and linkage to the full continuum of HIV prevention and treatment services, including Pre-exposure prophylaxis (PrEP) and highly active antiretroviral therapy (HAART). There is a need to better understand the effectiveness of the clinical interventions as received in this population, as well as the methods by which those interventions are delivered (navigation/mobile services).|
|Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)||Department of Health & Human Services||Rolling Submission||$275,000||The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).|
|Notice of Information: Contributing to the Global COVD-19 Crisis response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis||National Institutes of Health/DHSS||None Posted||Not Available||The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship. NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources.|
|Rapid Access for COVID-19 Research||Rapid Access for COVID-19 Research||None Posted||Not Available||With the continuing spread of the COVID-19 pandemic, the Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies.|
|COVID-19 Response Fund||International Associate for Volunteer Effort||None Posted||$500||The IAVE COVID-19 Response Fund will focus on supporting global volunteer leadership organizations working directly to respond to the pandemic among the most vulnerable populations in order to help build their capacity for response.|
|COVID-19 Rapid Response Fund||Southern Black Girls and Women's Consortium||None Posted||$10,000||The Southern Black Girls and Women's Consortium (SBGWC), a collective of funders, activists and community leaders working to advance the movements for black girls and women in the Deep South, is offering an immediate funding opportunity to support black girls and women and the people who rely on them due to the COVID-19 outbreak.|
|Deuteration & Macromolecular Crystallisation (DEMAX) COVID-19 related Research Projects||European Spallation Source||None Posted||Not Available||The Deuteration & Macromolecular Crystallisation (DEMAX) platform at ESS is offering prioritised access to laboratory services for scientists and researchers working on COVID-19-related research projects.|
|Ferring COVID-19 Investigational Grants||Ferring Pharmaceuticals||None Posted||EUR 25,000||Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects on SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The programme will provide a limited number of research grants up to €25,000 for each application.|
|COVID-19 Telehealth Program||Federal Communications Commission||None Posted||$1,000,000||The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis with enhancements to currently funded PCORI Dissemination and Implementation awards. Only PCORI-funded investigators or project leads with active Dissemination and Implementation Award contracts are eligible to submit a proposal in response to this announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$150,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trail Optional)||National Institutes of Health/DHSS||05-Oct-2020||Not Available||The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.|
|Artist Relief||Americans for the Arts||Not Available||$5,000||Artist Relief will distribute $5,000 grants to artists facing dire financial emergencies due to COVID-19; serve as an ongoing informational resource; and co-launch the COVID-19 Impact Survey for Artists and Creative Workers, designed by Americans for the Arts, to better identify and address the needs of artists.|
|Ecology and Evolution of Infectious Diseases (EEID)||National Science Foundation||11/18/2020||Not Available||The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.|
|SARS-COV-2 Diagnostics: Performance Data||Foundation for Innovative New Diagnostics (FIND)||Rolling Basis||Not Available||FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor's official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.|
|RFP - CSO COVID-19 Response||Department of the Air Force||9/30/2020||Not Available||Background & Authority The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE’s): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort. For full solicitation see Attachment 1 labeled CSO_COVID_19 Response FA3002_20_S_0002. Additional beta.sam.govinformation Notice Id f48d23af514f494f819f0c33e9f40e17 Source https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view Note: This link might not be valid after archive date below. Archive Date 10/15/2020 -----------------|
|Prototype Development to Combat COVID-19||DOD - Department of the Army||Projected mid-2020||TBD||The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). In light of the magnitude and potential threat that the coronavirus (COVID-19) poses to our military’s health and readiness, the Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.|
|Priority Access Call for Work on Combating COVID-19||Scherre (Paul) Institute||None Posted||Not Available||The Paul Scherrer Institute (PSI) has opened a "PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.|
|NIH Small Research Grant Program (Parent R03 Clinical Trail NOT Allowed)||National Institutes of Health/DHSS||On-going (Currently 07-Sept-2020)||$100,000.00||The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).|
|RFP -- AMENDMENT --- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement||Department of Health & Human Services||Continuous||Not Specified||AMENDMENT: 3/9/2020 - Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002). AMENDMENT: 3/18/2020 - Please see Special Instructions 004 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes of Health (multiple ICs)||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.
Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.
|Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 (NSF 20-065)||National Science Foundation||Four Submission Windows:|
3/6/ 2020 6/4/ 2020
6/5/2020 9/3/ 2020
|See SBIR/STTR Guidelines||The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nations and worlds ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program. All active NSF SBIR/STTR awardees, and other interested US-based small businesses are eligible to submit a Phase I proposal. Please reference the NSF SBIR and STTR Phase I solicitations for more details regarding eligibility.|
|Coronavirus Local Response Initiative||Bloomberg Philanthropies||Continuous Submission||Not Specified||Bloomberg Philanthropies will work with partners to identify the needs and lessons learned from cities experiencing the outbreak in real time that can be shared with additional cities eager to get ahead of the virus spread. Relying on public health expertise from the Johns Hopkins Bloomberg School of Public Health, the network will provide mayors with the most up-to-date information on the virus from the Centers for Disease Control and help them understand and act on the most relevant and accurate information available.
The program is open to all cities in the United States and will accommodate as many participants as possible. (tld)
|Dear Colleague Letter--Coronavirus Disease 2019 (COVID-19)||Department of Energy||Continuous Submission||Not Specified||Through its user facilities, computational power, and enabling infrastructure, DOE has unique capabilities that the scientific community may leverage for the COVID-19 response and recovery. DOE does not provide medical and clinical work; instead, the Department's mission complements the efforts of the National Institutes of Health, the Department of Defense, and other Federal partners by helping to understand the scientific phenomena contributing to COVID-19, from the structure of the SARS-CoV-2 virus, which causes the disease, to models that can mimic its spread. DOE supports significant biologically focused facilities and resources, including the Joint Genome Institute (JGI), National Microbiome Data Collaborative (NMDC), Environmental Molecular Science Laboratory (EMSL), and DOE Systems Biology Knowledgebase (KBase). These and other DOE resources may be used for many studies. The Department encourages submission of scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. The Department is acting rapidly to leverage, and when appropriate provide prioritized access to, the full range of DOE user facilities and other facilities available at national laboratories to support the national and international effort to address COVID-19.|
|Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)||Department of Health & Human Services||10/31/2020||Not Specified||NOTE: This program has been amended per the March 5, 2020 edition of FedBizOpps. Please see the amendment below. AMENDMENT: The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest until further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 will be accepted. All Areas of Interest are suspended except: a. AOI 7.7.1 Diagnostic Assay for human coronavirus using existing FDA-cleared platforms, b. AI 7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus c. AOI 7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection) d. AOI 8.3 COVID-19 Vaccine, e. AOI 9.2 COVID-19 Therapeutics, f. AOI 9.3 Immunomodulators or therapeutics targeting lung repair, and g. AOI 9.5 Pre-exposure and Post-exposure Prophylaxis, h. AOI 10 Respiratory Protective Devices, i. AOI 11 Ventilators. BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice. The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.
Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.|| The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 22.214.171.124 of the NIH Grants Policy Statement; https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.1_changes_in_project_and_budget.htm#Need) and will be routed directly to the Grants Management Officer of the parent award.
Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.
|Dear Colleague Letter on the Coronavirus Disease 2019(COVID-19); NSF 20-052||National Science Foundation||Varies||Varies||In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to email@example.com.
|Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19); NSF 20-055||National Science Foundation||Varies||Varies||This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge. Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program. Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream. To ensure availability of these computing resources, investigators must contact OAC prior to submission of the proposal.|
|Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)||National Heart, Lung and Blood Institute/National Institutes of Health/DHHS||Varies (NOSI Expires 10/06/2020)||Varies||NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals. To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations. Applicants should be submitted using one of the two Supplement PAs (PA-18-591 and PA-18-935)|
|Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus||National Institute on Drug Abuse/NIH/DHHS||Varies (NOSI Expires 3/31/2021)||Varies||NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder. Applicants should be submitted using one of the two Supplement PAs (PA-18-591, where the work proposed in the supplement is fully within the scope of the ongoing grant; and PA-18-935, for grantees wishing to expand the scope of their active grant)|
|Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)||National Institute of Allergy and Infectious Diseases (NIAID) and|
National Institute of General Medical Sciences (NIGMS)/NIH/DHHS
|Expiration Date of NOSI, 4/8/2020||Varies||NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
NIAID and NIGMS are therefore offering Competitive Revisions to active grants addressing research objectives described in the NOSI. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Further details can be found here: https://www.niaid.nih.gov/grants-contracts/urgent-award-mechanism. The funding instrument, or activity code, will be the same as the parent award.
Please note: NOT-AI-20-030 is specific for PA-18-935. NIH grantees seeking additional funds for research responsive to the 2019-nCoV outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action (IPA)||See website for deadlines and how to apply||$50,000||As COVID-19 spreads around the world, IPA's Peace & Recovery Program is accepting off-cycle proposals, capped at $50,000, for time-sensitive additions to research projects that study or support the COVID-19 response. Due to the limited funding available, this funding will likely not fund entire randomized evaluations, but is meant to support research projects with additions such as:
Adding a module to an existing survey in order to track COVID-19 exposure or response,
Adding a treatment arm that may support communities' resiliency in response to COVID-19,
Anonymizing, curating, and sharing already-collected data quickly so that it can be used for decision-making by the humanitarian community, or
Downstream surveys" that follow up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19. Interested applicants should first send an email to firstname.lastname@example.org asking for more information on how to submit an off-cycle proposal.